Wire open Last filed CagriSema REDEFINE 9 lower doses cut weight by about 21 percent in Phase 3 trial RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineINDNews

Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide

Eli Lilly started building a 3.5 billion dollar injectables and device site in Fogelsville, due to run by 2031. Its first named product, the triple hormone peptide retatrutide, is still in Phase 3 trials.

FOGELSVILLE, PA

$3.5BLilly investment in the Fogelsville injectables and device site, due to run by 2031
  1. What's newEli Lilly broke ground on a 3.5 billion dollar injectable medicine and device site in Fogelsville, Pennsylvania, first announced in February 2026, with about 850 permanent jobs planned.
  2. Why it mattersThe plant is built to make next generation obesity drugs, led by retatrutide, a triple hormone peptide that is still in Phase 3 trials and not approved anywhere.
  3. What's nextLilly expects the site to be running by 2031. No retatrutide filing date has been announced, so approval and demand remain open questions.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 20 Nov 2026An Italian cohort of 57,426 matched adults with type 2 diabetes found heart attack, stroke or death about twice as often after GLP 1 drugs were stopped, and deaths about 4.6 times as often.
  2. TRL · 20 Nov 2026An AHA 2026 records study of 256,492 matched adults with prediabetes and obesity linked GLP 1 drugs to more reversion to normal blood sugar and less diabetes than metformin.
  3. EXP · 19 Nov 2026An Alcami formulation scientist told PharmTech that polymethacrylate coatings, self emulsifying systems and solid dispersions can raise the oral bioavailability of peptides, and set them against the SNAC enhancer.
  4. TRL · 18 Nov 2026Priavoid said its oral all D peptide PRI 002 met the primary safety endpoint but missed the primary efficacy endpoint, CDR SB at week 48, in the 304 patient PRImus AD trial.
  5. TRL · 18 Nov 2026Aravax reported that monthly PVX108 shots met the primary endpoint of a Phase 2 trial in 71 children aged 4 to 11 with peanut allergy, with no anaphylaxis or treatment related serious events.

By the numbers

The one figure each story turns on.

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Desk fronts

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator18
  • Journal13
  • Company release30
  • Conference15
  • Our newsroom37